For its second fiscal quarter (ending June 30), Agios Pharmaceuticals Inc (NASDAQ: AGIO) has reported E.P.S. of $-1.69 compared to $-1.51 a year ago. For the latest four quarters through June 30, E.P.S. were $-6.50 versus $-3.79 for the same period a year ago.
Recent Price Action
Agios Pharmaceuticals Inc (NASDAQ: AGIO) stock declined by -4.1% on 8/1/24. The shares closed at $44.50. Trading volume in this decline was normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -7.7% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, AGIO is expected to be a modest Value Builder.
Agios Pharmaceuticals has a current Value Trend Rating of C (High Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Agios Pharmaceuticals has a poor Appreciation Score of 16 but a very high Power Rating of 96, triggering the High Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment